Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Secukinumab
Cosentyx
Routinely available
SMC (SMC2308)
29/03/2023
Indication
For the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with national guidance
Formulation
150mg solution for injection in pre-filled syringe and 150mg solution for injection in pre-filled pen (Cosentyx)
Comments
-